Immune checkpoint inhibitors (ICI) targeting programmed cell death-1 (PD-1) or cytotoxic T lymphocyte antigen-4 (CTLA-4) pathways have made great progress in breast cancer treatment. Here, CTLA4 is linked to breast cancer.